However, advances in genomic research would lead to a more precise approach using therapeutic targets that would also allow the development of new agents, prognostic or predictive biomarkers and a better understanding of resistance mechanisms. The following article is a comprehensive review of the approved and investigational drugs in pNET, and highlights the current concerns about treatment sequencing, but also provides an update of some of the present and future efforts for an improvement in the therapeutic algorithm of the disease.
INTRODUCTION
A wide spectrum of disease is observed in pancreatic neuroendocrine tumors (pNETs);
Electronic supplementary material The online version of this article (doi:10.1007/s40487-015-0007-6) contains supplementary material, which is available to authorized users. pNETs make up 3% of primary pancreatic malignancies and 12% of all gastroenteropancreatic neuroendocrine tumors (GEP NETs) [1] . Five-year overall survival (OS) rates range between 7% and 75% for patients with high and low-grade tumors, respectively [2] .
Goals of therapy for pNETs include not only the prolongation of life, but also the improvement of disease-related symptoms, and control of burden of disease and quality of life. Based on current molecular understanding, several therapies have demonstrated efficacy in pNETs, and novel drugs are still currently being investigated [3] . Treatment sequencing in these tumors is a novel concept, and has arisen from the availability of new, different and effective therapeutic agents. However, the correct place of those therapies within the treatment algorithm at each time of disease progression to achieve maximum impact in OS is still a matter of debate. Clinicians guide their decisions based on different parameters, but accurate biomarkers and information about sequencing coming from clinical trials are still lacking, and the wide spectrum of clinical behaviors in pNETs brings challenges in selecting the best treatment and monitoring response. Therefore, a multidisciplinary approach from expert physicians is essential in this particular group of patients belonging to a rare and complex disease [4] .
AN OVERVIEW OF PNETS
pNETs represent both a heterogeneous and a rare group of tumors with low frequency (0.32 diagnosed cases per 100,000 population per year) [5] . However, this figure has been increasing over recent years, as reported in a Japanese survey which showed an estimated prevalence of 2.69 per 100,000 in 2010, which corresponded to an increase of 1.2 times the number of patients with pNETs receiving oncological treatment compared to 2005 [6] . Improvement in diagnostic tools, increase in interest among physicians for the performance of particular radiological and nuclear images, [7] . Thus, the last updated classification from the World Health Organization (WHO) divided NETs into two different categories: (1) welldifferentiated (WD)-NETs G1 (mitotic count \2 9 10 high power field [HPF] and Ki67 index B2%) and G2 (mitotic count 2-20 9 10 HPF and Ki67 index 3-20); and (2) poorly differentiated (PD)-neuroendocrine carcinomas (NECs) G3
(mitotic count [20 9 10 HPF and Ki67 [20) [8] .
Recent advances in nuclear medicine using radiolabelled somatostatin analog (SSA) agents overcome challenging issues in the diagnostic and therapeutic assessment of NETs, such as the However, those data are not sufficient to consider MGMT status as an independent predictive factor, as prospective data are required to validate it. At the moment, target expression in NETs is not good enough to predict response; in fact, there is currently no definitive biomarker that could guide our therapeutic decisions in the clinic, not only because of its limited accuracy in sensitivity and specificity, such as with cromogranin A, but also for the technical efforts and costs required for the general applicability of the potential biomarkers proposed at the moment [30] .
Some of the following drugs and treatment strategies are currently being investigated, and study results look promising for clinicians to be able to place these agents into treatment algorithms for patients with pNETs.
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
The benefit of nuclear medicine in diagnosis and treatment of NETs is also currently being investigated in tumors of pancreatic origin, although the real value of peptide receptor radionuclide therapy (PRRT) in the different NET types and in which line should it be used is unclear [43] ( Table 2 continued However, data from a compassionate use program showed that patients treated with everolimus after PRRT and chemotherapy had a significant increased risk of toxicity and treatment discontinuation. Grade 3-4 adverse events were described in 87% of patients [47] . 
ANTIANGIOGENICS

FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) DUAL INHIBITORS
ALKYLATING AGENTS
Some cytotoxic agents have been investigated in pNETs due to the cumulative evidence showing higher sensitivity of this subtype of 
COMBINATION THERAPIES
Unfortunately, patients finally progress under initial systemic treatment and subsequent therapies are required as currently there are no agents able to cure the disease. Therefore, current research in NETs also focuses on the mechanisms of intrinsic or acquired resistance that interfere at some point of the disease in the majority of patients. Temozolomide-based regimens showed infectious complications due to the immunosuppressive effect due to prolonged exposures for more than 6 months [64] and cumulative toxicities from the temozolomide and thalidomide regimen, whereas 66% of patients discontinued treatment due to treatment-related toxicity. In the CLARINET trial, 3% of patients suffered from serious adverse events related to study treatment. The most frequent Grade 3-4 adverse events in the RADIANT-3 trial were stomatitis (7%), anemia (6%), hyperglycemia (5%) and thrombocytopenia (4%), and in the SUN1111 trial were neutropenia (12%), hypertension (10%) and diarrhea and asthenia (5%) [29, 33, 37] .
Treatment goals in pNETs include improvement of survival, relief of tumorrelated symptoms, inhibition of tumor growth, prevention of complications and maintenance of a good quality of life. According to these objectives, particular advantages from targeted therapies in pNETs include prolongation of disease control and survival with an acceptable safety profile that allows these drugs to be administered in a wide spectrum of the disease. Indeed, treatment with these agents is not associated with cumulative toxicity following therapeutic strategies, even in patients remaining on treatment for prolonged periods of time. In this context, combination strategies with 2 or 3 drugs are currently being investigated to try to offer a clinical benefit based on a theoretical synergy between agents that might overcome some mechanisms of escape without a significant increase in adverse events (Table 3) In addition to combination strategies, more information around sequencing strategies is required. An ongoing Phase III clinical trial, the SEQTOR trial, would allow the assessment of the real activity of this regimen with updated response criteria and would help assess the right treatment sequence for patients with pNETs, e.g., everolimus followed by streptozotocinfluorouracil or vice versa (Table 3) . 
